Biosimilars and Generics Threat to Tremfya: Market Impact Assessment

 With a valuation of USD 3.92 billion in 2024, the global Tremfya market is poised for sustained growth at a CAGR of 7.4% through 2034. This momentum is being propelled by country-specific developments in healthcare policy, regulatory frameworks, and corporate strategy. While Tremfya remains primarily marketed by Johnson & Johnson through its subsidiary Janssen Biotech, the drug’s success is closely tied to national policy impact, market share concentration, and strategic positioning within the broader biologics ecosystem.

The United States continues to serve as the cornerstone of Tremfya’s commercial success, benefiting from high per capita healthcare spending, broad insurance coverage, and a favorable regulatory environment. The Centers for Medicare & Medicaid Services (CMS) and private payers have recognized the drug’s clinical value, ensuring its inclusion in preferred formularies across major health plans. Strategic positioning by Janssen includes lifecycle management initiatives, such as new indications, pediatric labeling extensions, and long-term cardiovascular safety data, which reinforce Tremfya’s differentiation in a crowded IL-23 space.

China is emerging as a critical growth driver, with increased access to innovative biologics following regulatory reforms and expanded insurance coverage. The National Medical Products Administration (NMPA) has expedited the review process for foreign biologics, allowing Tremfya to enter the Chinese market more quickly than predecessors. Market share concentration remains relatively low compared to TNF inhibitors, but early entry positions Janssen to capitalize on rising demand for next-generation therapies in urban centers and tertiary hospitals.

Germany exemplifies a blend of technical sophistication and regulatory alignment within the European Union. The country’s Institute for Quality and Efficiency in Health Care (IQWiG) plays a pivotal role in determining reimbursement levels based on comparative effectiveness, giving Tremfya a competitive edge due to its proven long-term remission rates. R&D leadership is reinforced through collaborations with academic institutions and participation in pan-European registries aimed at evaluating real-world outcomes.

Read More @ https://www.polarismarketresearch.com/industry-analysis/tremfya-market

Corporate strategies among top-tier players reflect a dual emphasis on innovation leadership and geographic expansion. Mergers and acquisitions have become a preferred route for entering new therapeutic areas or acquiring complementary assets. For instance, recent strategic moves by AbbVie and Eli Lilly underscore the importance of building diversified portfolios in the IL-23 and IL-17 classes. Furthermore, joint ventures with local partners in high-growth markets allow global firms to navigate complex regulatory landscapes and establish localized manufacturing units that cater to regional demand.

R&D leadership is increasingly concentrated in innovation hubs located in Boston, Basel, and San Diego, where biotech incubators, venture capital funding, and academic-industry collaborations foster continuous advancement. Investment priorities include improving long-term durability, reducing injection frequency, and integrating digital tools into therapy monitoring. Cloud-based analytics, AI-driven biomarker identification, and patient-reported outcome platforms are further enhancing clinical decision-making and personalized medicine approaches.

Dominant players by market share include:

  • Johnson & Johnson (Janssen Biotech)
  • AbbVie Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Pfizer Inc.
  • Sanofi S.A.
  • Amgen Inc.
  • Bristol-Myers Squibb Company

These firms collectively represent a significant portion of the global market, each employing distinct strategic positioning tactics to maintain relevance amid evolving regulatory landscapes and shifting patient care models.

More Trending Latest Reports By Polaris Market Research:

Paper And Paperboard Packaging Market

Leukemia Therapeutics Market

Electric Ship Market

Facial Injectable Market

Revenue Cycle Management Market

Thermo Compression Forming market

Digital Printing for Tableware Market

North America Secure Logistics Market

Polysilicon Market

 

Comments

Post a Comment

Popular posts from this blog

Sustainable Practices in Ultrapure Water Treatment: Energy Efficiency and Waste Reduction

  Valued at USD 10.39 billion in 2024, the global ultrapure water treatment systems market is anticipated to grow at a CAGR of 4.5% over the next decade, driven by national policy impact, corporate expansion strategies, and intensified R&D leadership across key geographies. The United States, China, and Germany stand out as pivotal contributors to this growth, each leveraging unique combinations of regulatory frameworks, domestic innovation ecosystems, and international trade positioning to solidify their roles within the global ultrapure water treatment landscape. The United States remains the dominant force in the market, supported by a thriving ecosystem of semiconductor innovation, deep-pocketed venture capital, and federal funding mechanisms. The Department of Energy and National Institute of Standards and Technology (NIST) continue to fund advanced water purification research, accelerating the development of contaminant-specific filtration media and real-time analytic...
Read more

ersonalized Health Tech in the U.S.: How mHealth Apps Are Reshaping Wellness

  The U.S. mHealth apps market was valued at USD 16.51 billion in 2024, with a projected CAGR of 12.4% from 2025 to 2034.This country-level review highlights how the U.S., China, and Germany are shaping global dynamics through national policy impact, market share concentration, R&D leadership, and strategic positioning, and examines what these trends mean for major incumbents and innovators. The United States leads global app innovation, supported by comprehensive regulatory frameworks (FDA, CMS reimbursements) and widespread app adoption .National policy impact—including the 21st Century Cures Act and expansions in telehealth coverage—has encouraged private‑sector R&D leadership. Major U.S. firms like Teladoc and Omron have pursued strategic positioning through acquisitions (e.g., Teladoc’s acquisition of Livongo), integrating chronic care management tools and widening product portfolios. Market share concentration is increasing, especially among players able to align w...
Read more

Investment Outlook: U.S. C4ISR and Defense Electronics Sector

  Valued at USD 69.21 billion in 2034, the U.S. C4ISR market is positioned for durable and structured expansion, forecasted to grow at a compound annual growth rate (CAGR) of 3.68% from 2025 through 2034. This growth trajectory is underpinned by the critical role that command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) systems play in shaping 21st-century defense postures. As great-power competition intensifies and operational theatres become increasingly networked and multidomain, national policy impact and corporate R&D leadership have emerged as central drivers of market competitiveness and resilience. The U.S. remains the single largest contributor to global C4ISR spending, followed by China, Germany, the United Kingdom, Israel, and Japan—all nations whose strategies are fueling advancements in systems integration, electronic warfare, and real-time data exploitation. The United States accounts for over 35% of global C4ISR d...
Read more